In addition, the low DR4/DR5 expression in SH-SY5Y line that is totally resistant to co-treatment of EV-T and dinaciclib further supports good DR5 and/or DR4 expression as a prequisite for TRAIL and dinaciclib combination- based cancer therapeutic regimes. Here, TNFRSF10A is linked to cancer.